ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, dasatinib (DB01254) is an oral dual BCR/ABL and SRC family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (DrugBank: dasatinib).